Nonalcoholic fatty liver disease

Hepatic manifestation of obesity and the metabolic syndrome

Hima Boppidi, Sumanth R. Daram

Research output: Contribution to journalReview article

51 Citations (Scopus)

Abstract

Obesity is currently a worldwide epidemic, and will likely only increase in prevalence in the coming years. The incidence of the metabolic syndrome (MetS) seems to be paralleling obesity. The MetS is strongly linked to insulin resistance, abdominal obesity, diabetes mellitus, and dyslipidemia. Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of obesity and the MetS. Although not currently a formal component of the MetS, data suggest a very strong correlation between NAFLD and the MetS; insulin resistance appears to be the common factor. Nonalcoholic steatohepatitis (NASH) is a more advanced stage in the spectrum of NAFLD, which can progress to cirrhosis. Management strategies for NAFLD are conceivably similar to those for the MetS, which focus on lifestyle measures aimed at weight reduction and maintenance. The purpose of this review is to highlight the growing epidemic of obesity and the MetS, and the strong likelihood of an increase in the prevalence of the already widely existent combination of NAFLD/NASH. This article describes pharmacological treatments including novel therapies aimed at the hepatic pathophysiologic process, as well as surgical options. The increasing prevalence of obesity and the MetS places a large population at risk for developing hepatic failure. Therefore, NAFLD must be acknowledged as a major worldwide public health concern.

Original languageEnglish (US)
JournalPostgraduate Medicine
Volume120
Issue number2
DOIs
StatePublished - Jul 1 2008

Fingerprint

Obesity
Liver
Insulin Resistance
Abdominal Obesity
Non-alcoholic Fatty Liver Disease
Liver Failure
Dyslipidemias
Life Style
Weight Loss
Diabetes Mellitus
Fibrosis
Public Health
Maintenance
Pharmacology
Incidence
Therapeutics

Keywords

  • Metabolic syndrome
  • MetS
  • NAFLD
  • NASH
  • Nonalcoholic fatty liver disease
  • Nonalcoholic steatohepatitis
  • Obesity

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Nonalcoholic fatty liver disease : Hepatic manifestation of obesity and the metabolic syndrome. / Boppidi, Hima; Daram, Sumanth R.

In: Postgraduate Medicine, Vol. 120, No. 2, 01.07.2008.

Research output: Contribution to journalReview article

@article{c337608d7bab416a8b2a553eadffe966,
title = "Nonalcoholic fatty liver disease: Hepatic manifestation of obesity and the metabolic syndrome",
abstract = "Obesity is currently a worldwide epidemic, and will likely only increase in prevalence in the coming years. The incidence of the metabolic syndrome (MetS) seems to be paralleling obesity. The MetS is strongly linked to insulin resistance, abdominal obesity, diabetes mellitus, and dyslipidemia. Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of obesity and the MetS. Although not currently a formal component of the MetS, data suggest a very strong correlation between NAFLD and the MetS; insulin resistance appears to be the common factor. Nonalcoholic steatohepatitis (NASH) is a more advanced stage in the spectrum of NAFLD, which can progress to cirrhosis. Management strategies for NAFLD are conceivably similar to those for the MetS, which focus on lifestyle measures aimed at weight reduction and maintenance. The purpose of this review is to highlight the growing epidemic of obesity and the MetS, and the strong likelihood of an increase in the prevalence of the already widely existent combination of NAFLD/NASH. This article describes pharmacological treatments including novel therapies aimed at the hepatic pathophysiologic process, as well as surgical options. The increasing prevalence of obesity and the MetS places a large population at risk for developing hepatic failure. Therefore, NAFLD must be acknowledged as a major worldwide public health concern.",
keywords = "Metabolic syndrome, MetS, NAFLD, NASH, Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, Obesity",
author = "Hima Boppidi and Daram, {Sumanth R.}",
year = "2008",
month = "7",
day = "1",
doi = "10.3810/pgm.2008.07.1800",
language = "English (US)",
volume = "120",
journal = "Postgraduate Medicine",
issn = "0032-5481",
publisher = "Medquest Communications LLC",
number = "2",

}

TY - JOUR

T1 - Nonalcoholic fatty liver disease

T2 - Hepatic manifestation of obesity and the metabolic syndrome

AU - Boppidi, Hima

AU - Daram, Sumanth R.

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Obesity is currently a worldwide epidemic, and will likely only increase in prevalence in the coming years. The incidence of the metabolic syndrome (MetS) seems to be paralleling obesity. The MetS is strongly linked to insulin resistance, abdominal obesity, diabetes mellitus, and dyslipidemia. Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of obesity and the MetS. Although not currently a formal component of the MetS, data suggest a very strong correlation between NAFLD and the MetS; insulin resistance appears to be the common factor. Nonalcoholic steatohepatitis (NASH) is a more advanced stage in the spectrum of NAFLD, which can progress to cirrhosis. Management strategies for NAFLD are conceivably similar to those for the MetS, which focus on lifestyle measures aimed at weight reduction and maintenance. The purpose of this review is to highlight the growing epidemic of obesity and the MetS, and the strong likelihood of an increase in the prevalence of the already widely existent combination of NAFLD/NASH. This article describes pharmacological treatments including novel therapies aimed at the hepatic pathophysiologic process, as well as surgical options. The increasing prevalence of obesity and the MetS places a large population at risk for developing hepatic failure. Therefore, NAFLD must be acknowledged as a major worldwide public health concern.

AB - Obesity is currently a worldwide epidemic, and will likely only increase in prevalence in the coming years. The incidence of the metabolic syndrome (MetS) seems to be paralleling obesity. The MetS is strongly linked to insulin resistance, abdominal obesity, diabetes mellitus, and dyslipidemia. Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of obesity and the MetS. Although not currently a formal component of the MetS, data suggest a very strong correlation between NAFLD and the MetS; insulin resistance appears to be the common factor. Nonalcoholic steatohepatitis (NASH) is a more advanced stage in the spectrum of NAFLD, which can progress to cirrhosis. Management strategies for NAFLD are conceivably similar to those for the MetS, which focus on lifestyle measures aimed at weight reduction and maintenance. The purpose of this review is to highlight the growing epidemic of obesity and the MetS, and the strong likelihood of an increase in the prevalence of the already widely existent combination of NAFLD/NASH. This article describes pharmacological treatments including novel therapies aimed at the hepatic pathophysiologic process, as well as surgical options. The increasing prevalence of obesity and the MetS places a large population at risk for developing hepatic failure. Therefore, NAFLD must be acknowledged as a major worldwide public health concern.

KW - Metabolic syndrome

KW - MetS

KW - NAFLD

KW - NASH

KW - Nonalcoholic fatty liver disease

KW - Nonalcoholic steatohepatitis

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=54049091645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54049091645&partnerID=8YFLogxK

U2 - 10.3810/pgm.2008.07.1800

DO - 10.3810/pgm.2008.07.1800

M3 - Review article

VL - 120

JO - Postgraduate Medicine

JF - Postgraduate Medicine

SN - 0032-5481

IS - 2

ER -